Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies.
Shedding of a pharmacological target from cells, giving rise to a soluble target that can also bind therapeutic proteins, is a common phenomenon. In this study, a minimal physiologically based pharmacokinetic model was used to simulate the pharmacokinetics of trastuzumab and the simultaneous binding of the compound to soluble (in blood and tissue interstitial space) and membrane-bound (in the tissue interstitial space) forms of human epidermal growth factor receptor 2 (HER2). The parameter values describing binding of trastuzumab to HER2 were largely derived from in vitro data, and the effects of varying HER2 levels, the affinity difference between membrane-bound HER2 and shed antigen, and slow binding kinetics were investigated. The model simulates a sharp decrease in trough drug concentrations at concentrations of soluble target between 500 and 1,000 ng/ml in plasma. This corresponds with the clinical concentration range of soluble target wherein changes in half-life of trastuzumab have been observed.CPT Pharmacometrics Syst. Pharmacol. (2014) 3, e96; doi:10.1038/psp.2013.73; published online 29 January 2014.
Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
L
L
Li
Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
I
I
Gardner
Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
R
R
Rose
Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield, UK.
M
M
Jamei